Overview

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Bristol-Myers Squibb
Collaborator:
AstraZeneca
Treatments:
Metformin
Saxagliptin